Commentary: The Real-world Convergence of Comparative Effectiveness Research and Risk-Benefit Assessment

Baghdadi R. FDA considering “super office” of drug safety within drug center. RPM Report, March 25, 2011; http://therpmreport.com/Free/9ac0ed7b-3afe-4fe3-b04c-ced675140264.aspx?utm_source=RPMel.

Eastman P. ODAC backs FDA's strong stance on need for post-marketing studies on accelerated-approval cancer drugs. Oncology Times. February 11, 2011; http://journals.lww.com/oncology-times/Fulltext/2011/02250/ODAC_Backs_FDA_s_Strong_Stance_on_Need_for.3.aspx.

Goldberg NH Schneeweiss S Kowal MK Gagne JJ . Availability of comparative efficacy data at the time of drug approval in the United States. JAMA. 2011; 305:1786–1789; http://jama.ama-assn.org/content/305/17/1786.short.

Jenkins J. A United States regulator's perspective on risk-benefit considerations. FDA presentation, April 23, 2010; http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM210155.pdf.

Slotnik J. CMS-FDA proposed premarket parallel review—the devil is in the details. Value-Based Cancer Care; http://valuebasedcancer.com/article/cms-fda-proposed-premarket-parallel-review%E2%80%94-devil-details.

Memorandum of understanding between United States Food and Drug Administration and Centers for Medicare and Medicaid Services. Fed Register. 48699, August 11, 2010; http://www.federalregister.gov/articles/2010/09/17/2010-23252/parallel-review-of-medical-products.

Chambers JD Neumann PJ . Listening to Provenge—what a costly cancer treatment says about future Medicare policy. NEJM. May 5, 2011; http://www.nejm.org/doi/full/10.1056/NEJMp1103057.

Pollack A. Medicare will pay for prostate drug. New York Times, June 30, 2011; http://prescriptions.blogs.nytimes.com/2011/06/30/medicare-will-pay-for-prostate-cancer-drug/.